CONy 2023 | Blocking CGRP in migraine patients: cardiovascular implications

Vlasta Vukovic Cvetković, MD, PhD, University Hospital Glostrup, Danish Headache Center, Copenhagen, Denmark, discusses whether monoclonal antibodies targeting the CGRP system should be avoided in migraine patients with vascular risk factors. CGRP is a potent vasodilator and is important in maintaining cardiovascular homeostasis. Therefore, the use of anti-CGRP treatments in migraine patients with vascular risks is theoretically problematic. Despite the cardiovascular implications, treatment with CGRP antibodies has shown no relevant cardiovascular side effects. However, results from long-term trials and real-world studies are needed. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.